Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01492582 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,499
- Enrollment target
NCT01492582: Completed Phase 2 study, sponsored by University of Alabama at Birmingham.
NCT01492582 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 1,499 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1027% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01492582, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,499 participants
- Enrollment target
Study Summary
This trial will comprehensively evaluate the human papillomavirus (HPV) vaccine in cancer survivors between 9 and 26 years of age by (1) determining the prevalence of HPV vaccine initiation among young cancer survivors, and (2) determining the immune response to and safety/tolerability of the quadrivalent and nonavalent HPV vaccine in young cancer survivors.
Primary Outcome
The prevalence of HPV vaccine initiation in cancer survivors ages 9 to 26 years
Interventions
- OTHER laboratory biomarker analysis
- OTHER medical chart review
- OTHER survey administration
- BIOLOGICAL quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,499 participants |
| Start Date | 2012-07 |
| Est. Completion | 2020-07-20 |
| Phase | Phase 2 |
What the finished NCT01492582 record still lists
NCT01492582 is an interventional study that assigns participants to a tested intervention. Its 1,499 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1027% higher).
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT01492582 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01492582 about?
NCT01492582 is a clinical study titled "Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors". This trial will comprehensively evaluate the human papillomavirus (HPV) vaccine in cancer survivors between 9 and 26 years of age by (1) determining the prevalence of HPV vaccine initiation among young cancer survivors, and (2) determining the immune response to and safety/tolerability of the quadri...
What is the current status of trial NCT01492582?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,499 participants. The study started on 2012-07. Estimated completion is 2020-07-20.
What interventions are being tested in trial NCT01492582?
The interventions under investigation include: laboratory biomarker analysis (OTHER), medical chart review (OTHER), survey administration (OTHER), quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01492582?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01492582's enrollment target sits among peer trials
1,499 12th of 2000 higher than 1,989 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia